Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bunker

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Physiological Reports|November 17, 2025
Effects of a novel acetaminophen analog on cardiorespiratory compensatory responses and survival in a male rat model of traumatic hemorrhageMiryam M Pando, Kathy L Ryan, Mariam L Calderon, et al.
Science (New York, N.Y.)|April 25, 2020
Mechanisms of OCT4-SOX2 motif readout on nucleosomesAlicia K Michael, Ralph S Grand, Luke Isbel, et al.
Nature Communications|November 19, 2025
A degron-mimicking molecular glue drives CRBN homo-dimerization and degradationGerasimos Langousis, Pablo Gainza, Moritz Hunkeler, et al.
Journal of Medicinal Chemistry|July 14, 2025
Discovery of ZN-c5, an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) with Improved PharmacokineticsSayee G Hegde, Peter Q Huang, Kevin D Bunker, et al.
Molecular Cancer Therapeutics|April 15, 2025
Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumorsJianhui Ma, Wen Liu, Jiali Li, et al.
Nature|April 1, 2016
Cullin-RING ubiquitin E3 ligase regulation by the COP9 signalosomeSimone Cavadini, Eric S Fischer, Richard D Bunker, et al.
Molecular Cell|May 10, 2011
Histone methylation by PRC2 is inhibited by active chromatin marksFrank W Schmitges, Archana B Prusty, Mahamadou Faty, et al.
Molecular Cell|June 30, 2019
Structural Basis of BRCC36 Function in DNA Repair and Immune RegulationJulius Rabl, Richard D Bunker, Andreas D Schenk, et al.
Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
NPJ Precision Oncology|January 4, 2025
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersDaehwan Kim, Heekyung Chung, Wen Liu, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Physiological Reports|November 17, 2025
Effects of a novel acetaminophen analog on cardiorespiratory compensatory responses and survival in a male rat model of traumatic hemorrhageMiryam M Pando, Kathy L Ryan, Mariam L Calderon, et al.
Science (New York, N.Y.)|April 25, 2020
Mechanisms of OCT4-SOX2 motif readout on nucleosomesAlicia K Michael, Ralph S Grand, Luke Isbel, et al.
Nature Communications|November 19, 2025
A degron-mimicking molecular glue drives CRBN homo-dimerization and degradationGerasimos Langousis, Pablo Gainza, Moritz Hunkeler, et al.
Journal of Medicinal Chemistry|July 14, 2025
Discovery of ZN-c5, an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) with Improved PharmacokineticsSayee G Hegde, Peter Q Huang, Kevin D Bunker, et al.
Molecular Cancer Therapeutics|April 15, 2025
Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumorsJianhui Ma, Wen Liu, Jiali Li, et al.
Nature|April 1, 2016
Cullin-RING ubiquitin E3 ligase regulation by the COP9 signalosomeSimone Cavadini, Eric S Fischer, Richard D Bunker, et al.
Molecular Cell|May 10, 2011
Histone methylation by PRC2 is inhibited by active chromatin marksFrank W Schmitges, Archana B Prusty, Mahamadou Faty, et al.
Molecular Cell|June 30, 2019
Structural Basis of BRCC36 Function in DNA Repair and Immune RegulationJulius Rabl, Richard D Bunker, Andreas D Schenk, et al.
Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
NPJ Precision Oncology|January 4, 2025
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersDaehwan Kim, Heekyung Chung, Wen Liu, et al.
Pageof 11